FreeOx Biotech

FreeOx Biotech is a late-stage clinical biopharmaceutical company dedicated to developing cerebrovascular protective therapies, a new drug for the emergency treatment of patients with acute ischemic stroke (AIS). By focusing on restoring microcirculatory homeostasis and enhancing penumbral reperfusion, the company aims to advance stroke care and improve patient outcomes. It is building a pipeline based on proprietary liposome formulation technology, which broadly expands opportunities in the field of neurology.